|2.||Wound Infection (Wound Infections)
|1.||Mota, A: 17 articles (05/2015 - 07/2005)|
|2.||Safranow, Krzysztof: 16 articles (06/2015 - 03/2006)|
|3.||Pawlik, Andrzej: 15 articles (06/2015 - 03/2006)|
|4.||Ciechanowski, Kazimierz: 15 articles (01/2015 - 03/2006)|
|5.||Parikh, Chirag R: 13 articles (12/2015 - 03/2004)|
|6.||Domanski, Leszek: 13 articles (06/2015 - 03/2006)|
|7.||Macário, F: 13 articles (05/2015 - 07/2005)|
|8.||Legendre, Christophe: 13 articles (01/2015 - 05/2002)|
|9.||Figueiredo, A: 12 articles (05/2015 - 07/2005)|
|10.||Parada, B: 12 articles (05/2015 - 07/2005)|
06/01/2009 - "Compared to HBD kidneys, CNHBD kidneys had more HLA mismatches and significantly more delayed graft function (44% versus 14%), and the mean time to halving of serum creatinine was significantly greater (12.8 versus 5 days). "
01/01/2009 - "Machine perfusion also significantly improved the rate of the decrease in the serum creatinine level and reduced the duration of delayed graft function. "
12/01/2003 - "Delayed graft function (DGF) (absent spontaneous reduction of serum creatinine day 1) was 51%. "
12/01/2015 - "Multivariate analysis of delayed graft function in kidney recipients matched to donors indicated that higher terminal creatinine level was associated with delayed graft function in recipients (P < .001). "
10/01/2015 - "Significantly more patients in the AKI group had delayed graft function (P = 0.006), prolonged hospital stay (P < 0.001) and high creatinine at discharge (P = 0.002). "
|2.||Muromonab-CD3 (Muromonab CD3)FDA Link
09/01/1992 - "Indirect evidence exists that a prophylactic course of OKT3 may be beneficial in immunologically high-risk patients and in patients with delayed graft function. "
02/01/1990 - "Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function."
10/01/1991 - "Reduced delayed graft function (DGF) after cadaveric kidney transplantation (CKT) with selective OKT3 induction and aggressive intraoperative management."
02/01/1990 - "We conclude that OKT3 induction provides superior results over CsA induction at doses given in renal allograft recipients with delayed graft function without a significant increase in morbidity or mortality and permits the reuse of OKT3 for treatment of rejection in most cases."
11/01/1989 - "OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function."
|3.||Diltiazem (Cardizem)FDA LinkGeneric
09/01/1989 - "Diltiazem given both to donor grafts and to recipients produced a significant reduction in the rate of delayed graft function but failed to improve one-year graft survival. "
01/01/1987 - "Prevention of delayed graft function in cadaver kidney transplants by diltiazem: outcome of two prospective, randomized clinical trials."
02/01/1996 - "Delayed graft function of cadaveric renal transplants is prevented by diltiazem."
01/01/1994 - "For the remaining 35 grafts no beneficial effect of treatment with diltiazem was found for the rate of delayed graft function, the rate of rejections, time to first rejection, whole blood CsA concentration, or graft function. "
12/14/1985 - "Prevention of delayed graft function in cadaver kidney transplants by diltiazem."
|4.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
06/15/2001 - "The expression of ICAM-1 molecules on tubular cells was determined to be a predictor for the occurrence of delayed graft function in cadaveric kidneys (ICAM-1: 65+/-24* vs. 38+/-29% delayed graft versus primary graft function). "
03/01/1999 - "In addition, in transplanted kidneys, ICAM-1 inhibition by antisense ODN ameliorates ischemia-reperfusion injury and prevents delayed graft function. "
08/01/1998 - "ICAM-1 inhibition ameliorates ischemia-reperfusion injury and prevents delayed graft function. "
10/01/2010 - "Reports suggest that there are genetic variations in ICAM-1 and VCAM-1 synthesis that can contribute to delayed graft function (DGF) and acute renal rejection after kidney transplantation. "
06/15/2001 - "To assess whether the number of cell adhesion molecules expressed in donor kidneys can predict early rejection or delayed graft function, kidney biopsies from 20 living and 53 cadaveric kidney donors were obtained before engraftment into the recipients and the expression of the cell adhesion molecules intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and endothelial leukocyte adhesion molecule (E-selectin) were determined by immunohistochemistry. "
03/01/2007 - "In conclusion, this study confirmed the beneficial effects of addition of basiliximab to the immunosuppressive schema of patients with delayed graft function."
11/15/2008 - "The incidence of delayed graft function did not significantly differ between the cohorts (10% and 13%, in basiliximab and control group). "
06/01/2008 - "Basiliximab may reduce the incidence of delayed graft function. "
01/01/2008 - "There was no hyperacute rejection in two groups, and delayed graft function occurred in two patients of ATG group and three of basiliximab group. "
03/01/2010 - "We sought to evaluate the efficacy of renal transplant induction protocols using Basiliximab based on the rates of acute rejection episodes (ARE) and delayed graft function (DGF) of infectious complications in the first 6 months posttransplant, as well as patient and graft survivals. "
|6.||Sirolimus (Rapamycin)FDA Link
03/01/2008 - "The duration of delayed graft function was longer in sirolimus group compared with the reference group (21.2 +/- 12.2 days vs 6.8 +/- 2.5 days) (P < .004). "
03/01/2008 - "There was an equal frequency of delayed graft function in the sirolimus group compared with the reference group (39% vs 34.8%). "
09/01/2006 - "Animal models suggesting that sirolimus may delay recovery in this setting have been supported by non-randomized experiences at single centers, which have observed an increased incidence of delayed graft function among sirolimus-treated recipients. "
01/01/2006 - "The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes. "
07/15/2012 - "The activity of mTOR complex 1 (mTORC1) is necessary for renal regeneration and repair after AKI, and inhibition of mTORC1 by rapamycin has been shown to delay recovery from ischemic AKI in animal studies, and to prolong delayed graft function in humans who have received a kidney transplant. "
06/01/2005 - "However, age (49.8, 50.4, 49.8, and 43.5 years, P < .05), panel reactive antibodies (22%, 39%, 27%, 34%, P < .05) and time of delayed graft function (12, 7, 3, 6 days, P < .05) were significantly different between the four groups. "
09/27/2003 - "For patients with delayed graft function, the protocol permitted reduced C2 targets and prophylactic administration of antibodies. "
08/01/2003 - "The aim was to study the incidence, impact, and association of pretransplantation anti-HLA antibodies and delayed graft function (DGF) on the outcome of cadaver kidney transplants independent of the immunosuppressive therapy. "
01/01/2013 - "Multivariate analysis identified the number of HLA mismatches (hazard ratio [HR] 1.25, 95% CI 1.01-1.56), panel reactive antibodies (HR 2.61, 95% CI 1.28-5.26), and delayed graft function (HR 11.25, 95% CI 1.33-95.28) as being significantly associated with graft loss after 15 years. "
01/01/2012 - "There were statistically significant differences in the incidences of delayed graft function, 1-year acute rejection rate, death-censored graft survival, and patient survival between the 2 groups, even though the ATG group had more kidney transplants from deceased donors, higher levels of panel reactive antibodies, and more retransplantations. "
|8.||mycophenolate mofetil (Cellcept)FDA LinkGeneric
10/01/2014 - "There were no differences in the incidence of acute renal graft rejection, delayed graft function, graft loss, and death in patients with Myfenax vs original CellCept and other formulations of mycophenolate. "
02/01/1999 - "Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. "
07/01/2005 - "Large-scale clinical trials using C(2) monitoring of cyclosporine (CsA) microemulsion (Neoral) in renal transplant recipients have demonstrated low acute rejection rates and good tolerability with a low adverse event profile in a variety of settings: with or without routine induction therapy; in combination with mycophenolate mofetil; with standard-exposure or low-exposure Neoral; and in patients with immediate or delayed graft function. "
03/01/1998 - "The pharmacokinetics of mycophenolic acid (MPA), the immunosuppressant form of the prodrug mycophenolate mofetil (MMF), and the primary glucuronide metabolite, MPAG, were characterized in renal transplant patients with delayed graft function using random effects piecewise linear models. "
03/02/2000 - "We analyzed the influence of demographic characteristics (age, sex, and race), transplant-related variables (living or cadaveric donor, panel-reactive antibody titer, extent of HLA matching, and cold-ischemia time), and post-transplantation variables (presence or absence of acute rejection, delayed graft function, and therapy with mycophenolate mofetil and tacrolimus) on graft survival for all 93,934 renal transplantations performed in the United States between 1988 and 1996. "
05/01/2003 - "The second study was a prospective trial of calcineurin inhibitor-free regimen in patients with severe delayed graft function (DGF) (requiring dialysis). "
05/01/2012 - "Advanced donor age, delayed graft function, calcineurin toxicity and repeated acute rejection episodes are risk factors for this pathophysiology. "
03/01/2010 - "Donor/recipient age, sex, panel reactive antibody (PRA), HLA mismatches, cold ischemia time, delayed graft function, acute rejection, blood pressure and its treatment, diabetes and anti-calcineurin use were also evaluated. "
01/01/2009 - "The "window of opportunity" to distinguish between acute rejection and calcineurin inhibitor nephrotoxicity is narrow in delayed graft function. "
10/01/2004 - "Nevertheless, the best calcineurin inhibitor should be decided on individual patients according to variable risk factors, such as risk of rejection in sensitized patient or delayed graft function. "
05/01/2011 - "Multiple models were adjusted for recipient sex, recipient age, donor age, ESA therapy, acute rejection episodes (ARE), days of delayed graft function, human leukocyte antigen mismatches and cold ischemia time. "
09/27/2009 - "Retransplantation, human leukocyte antigen match, antibody titer, expanded criteria donors, race, cytomegalovirus status, delayed graft function, and immunologic risks were similar between the two induction groups. "
10/01/2015 - "Cox proportional hazard modeling showed male gender, younger recipient age, black race, delayed graft function, human leukocyte antigen (HLA) mismatch ≥3 and increasing donor age to be significantly predictive for the composite efficacy endpoint at months 12 or 24 post-transplant. "
11/15/2008 - "Apart from human leukocyte antigen-DR mismatches, delayed graft function and age at renal transplantation, acute rejection was also predicted by the [ABCB1 +1236C; +2677G; +3435T] haplotype. "
03/01/2005 - "A total of 164 patients underwent early withdrawal: 82% had at least one mismatched DR antigen, 17% had delayed graft function, 33% were African American, and 18% were repeat transplant recipients. "
10/15/2012 - "Pharmacologic targeting of PKC may be beneficial for recipients receiving renal transplants at risk for delayed graft function."
03/15/2000 - "Omission of the pre-transplant XM was associated with a significant reduction in cold ischemic time (15.0 hr vs. 18.2 hr, P=0.01) and a reduced incidence of delayed graft function (13% vs. 33%, P=0.03). "
03/01/2004 - "This tool has now been shown to be effective in managing African-American renal transplants and those with delayed graft function. "
10/01/2009 - "Increased eGFR correlated with subsequent improvement in graft function (r = -.806; P = .001), and resistive index (RI) of the renal artery was inversely related to subsequent delayed graft function (r = .544; P = .029). "
09/01/2007 - "Improvement in early graft function and decreased delayed graft function (DGF) rates are some of the clinical benefits of TG. "
|2.||Transplantation (Transplant Recipients)
07/01/2010 - "Protocol biopsies need to be performed in the following clinical conditions: at the time of transplantation to obtain information about the transplanted kidney; in the case of prolonged delayed graft function; in patients at increased immunological risk; and in the case of clinical trials performed to assess the safety and efficacy of new immunosuppressive drugs."
01/01/2009 - "Hypothermic machine perfusion was associated with a reduced risk of delayed graft function and improved graft survival in the first year after transplantation. "
11/01/2015 - "A high Body Mass Index (BMI) predicts delayed graft function, all cause and cardiovascular death after transplantation but such risk excess is apparently confined to patients included in studies performed before 2000. "
07/01/2013 - "Studies are currently ongoing to determine its efficacy and safety in ABO incompatible transplantation, in the prevention of acute and chronic rejection either with a living or a deceased donor kidney as well as in the prevention of delayed graft function. "
04/01/2013 - "The objective of this study was to determine the impact of meeting DMGs on delayed graft function (DGF) in renal transplant recipients. "
|3.||Homologous Transplantation (Allograft)
07/01/2007 - "Efficacy of early biopsy in kidney allograft recipients with delayed graft function."
01/01/2015 - "The aim of this study was the analysis of relative telomere length (RTL; T/S ratio) in the biopsy specimens of the transplanted kidney allograft and its correlation with the delayed graft function (DGF), acute rejection (AR) and chronic allograft dysfunction (CAD). "
11/01/2013 - "As second-generation RIPK1 and RIPK3 inhibitors become available, clinical trials for the prevention of delayed graft function and attenuation of allograft rejection-mediated injury will emerge. "
05/01/2009 - "However, these studies were likely underpowered and often unadjusted, and multicenter studies have suggested HTK preservation might increase delayed graft function (DGF) and reduce graft survival of renal allografts. "
11/01/2006 - "The aim of the present study was to examine the release of adhesion molecules during the first minutes of kidney allograft reperfusion in relation to delayed graft function and acute graft rejection. "
11/01/2009 - "The European Machine Preservation Trial (MPT) found a significantly lower rate of delayed graft function and improved graft survival in machine-perfused kidneys compared to cold-stored kidneys in the first year following kidney transplantation. "
04/01/2012 - "Hypothermic machine preservation (HMP) has been used in renal transplantation since the late 1960s with recent robust prospective, multicenter data showing lower rates of delayed graft function and improved graft survival. "
10/01/2015 - "The purpose of this study was to analyze the risk factors for delayed graft function (DGF) and determine its impact on the outcomes of deceased donor (DD) kidney transplantation (KT). "
10/01/2014 - "The results of that study showed that mean arterial pressure, central venous pressure, and pulmonary capillary wedge pressure values of the donor importantly influence the frequency of delayed graft function after renal transplantation. "
11/27/2013 - "Delayed graft function (DGF) after renal transplantation can be diagnosed according to several different definitions, complicating comparison between studies that use DGF as an endpoint. "
|5.||Heart Transplantation (Grafting, Heart)
01/01/2008 - "Use of sirolimus with mycophenolate mofetil or azathioprine to avoid CNI exposure de novo has improved glomerular filtration rate for at least two yr in most studies in kidney transplantation; however, experience is limited in liver and heart transplantation, and reports of delayed graft function and wound healing with sirolimus may have dampened enthusiasm for de novo use. "